Dive Brief:

简报：

Gilead Sciences is looking at a new way to attack cancer, buying into a preclinical program from the Swedish biotech Sprint Bioscience.

吉利德科学公司正在寻找一种治疗癌症的新方法，购入了瑞典生物技术公司Sprint Bioscience的临床前项目。

The deal

交易

announced Monday

周一宣布

centers on a target known as

围绕一个被称为目标的中心

TREX1

TREX1

. Research suggests a healthy TREX1 gene can help prevent overactivation of the immune system that leads to conditions such as lupus, but it may also help cancer cells hide from the body’s natural attackers. In oncology, researchers are trying to inhibit TREX1 to

研究表明，健康的TREX1基因有助于防止免疫系统过度激活而导致狼疮等疾病，但它也可能帮助癌细胞躲避免疫系统的天然攻击者。在肿瘤学中，研究人员正试图抑制TREX1以...

unleash anti-tumor

释放抗肿瘤

immune activity.

免疫活性。

“TREX1 has demonstrated significant potential in the preclinical phase,” Sprint Bioscience CEO Johan Emilsson said in a statement. The new agreement calls for Gilead to pay Sprint $14 million up front and as much as $400 million more if the program meets certain clinical, regulatory and commercial milestones..

“TREX1 在临床前阶段已展现出显著潜力，”Sprint Bioscience 首席执行官 Johan Emilsson 在一份声明中表示。根据新协议，Gilead 将向 Sprint 支付 1400 万美元的预付款，并在项目达到特定的临床、监管和商业里程碑时，再支付高达 4 亿美元的款项。

Dive Insight:

深入洞察：

Gilead has bet billions of dollars on its oncology program, most notably five years ago with the $21 billion buyout of

吉利德已经为其肿瘤学项目投入了数十亿美元，最引人注目的是五年前以210亿美元收购了

Immunomedics

免疫医疗公司

that came with the cancer drug Trodelvy. That drug, however, has

随着癌症药物Trodelvy附带的。然而，该药物具有

failed

失败

so far to live up to initial expectations while also hitting some research setbacks. In 2024, Gilead said it would no longer sell Trodelvy for

到目前为止，它既达到了最初的预期，但在研究方面也遇到了一些挫折。2024年，吉利德表示将不再出售Trodelvy用于

bladder cancer

膀胱癌

after a study failed to confirm the medicine’s clinical benefits.

在一项研究未能证实该药物的临床益处之后。

At the same time, Gilead is facing increased competition for its cell therapy business. And while the company’s HIV franchise has helped it ride out the challenges in oncology, that business faces a great deal of regulatory uncertainty as the Trump administration targets HIV programs.

同时，吉利德的细胞治疗业务面临越来越多的竞争。尽管该公司的艾滋病毒特许经营权帮助它度过了肿瘤学领域的挑战，但随着特朗普政府针对艾滋病项目，该业务面临着很大的监管不确定性。

So, Gilead is continuing to look externally for drugs that can eventually provide a business boost. In August, the company announced a $350 million deal to buy

因此，吉利德继续对外寻找能够最终提供业务增长的药物。八月，该公司宣布了一项3.5亿美元的收购交易。

Interius BioTherapeutics

内部生物治疗学

and its technology that can genetically modify immune cells inside the body.

其技术可以对体内的免疫细胞进行基因改造。

The latest deal with Sprint gives Gilead yet another new option with relatively little risk, as the vast majority of the proposed payouts are contingent on the program’s success.

与Sprint的最新交易使Gilead又获得了一个风险相对较小的新选择，因为绝大部分预期付款都取决于该计划的成功。